POLB.F

Poolbeg Pharma OTCPK:POLB.F Stock Report

Last Price

US$0.073

Market Cap

US$56.8m

7D

0%

1Y

n/a

Updated

11 Jan, 2023

Data

Company Financials +

POLB.F Stock Overview

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.

POLB.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Poolbeg Pharma PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poolbeg Pharma
Historical stock prices
Current Share PriceUK£0.073
52 Week HighUK£0.12
52 Week LowUK£0.073
Beta0
1 Month Change-36.52%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-27.00%

Recent News & Updates

Recent updates

Shareholder Returns

POLB.FUS PharmaceuticalsUS Market
7D0%-1.0%4.5%
1Yn/a7.0%-17.5%

Return vs Industry: Insufficient data to determine how POLB.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how POLB.F performed against the US Market.

Price Volatility

Is POLB.F's price volatile compared to industry and market?
POLB.F volatility
POLB.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement7.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: Insufficient data to determine POLB.F's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine POLB.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20217Jeremy Skillingtonhttps://www.poolbegpharma.com

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.

Poolbeg Pharma PLC Fundamentals Summary

How do Poolbeg Pharma's earnings and revenue compare to its market cap?
POLB.F fundamental statistics
Market CapUS$56.81m
Earnings (TTM)-US$3.78m
Revenue (TTM)n/a

0.0x

P/S Ratio

-15.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
POLB.F income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£3.11m
Earnings-UK£3.11m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0062
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did POLB.F perform over the long term?

See historical performance and comparison